PI3K/Akt, Wnt/β-catenin, TGF-β, Nrf2 and Notch signaling pathways are mainly involved in the TCM treatment of chronic refractory wounds (CRW). Chinese materia medica monomers and compound preparations can inhibit protein kinases related to signaling pathways in wound tissue and promote wound healing; reduce the expression of inflammatory factors and inhibit the occurrence of inflammatory response; promote the proliferation and differentiation of growth factors and epidermal stem cells, accelerate the regeneration of granulation tissue, and play a role in repairing wound regeneration.

Objective To quantify the risk factors for aspirin resistance so as to increase the prognosis for risk of coronary heart disease,and to establish a predictive model for aspirin resistance in order to guide the clinical anti-platelet therapy.Methods A total of 938 elderly male patients with stable coronary heart disease (CHD) receiving oral aspirin therapy (＞75 mg/d) over 2 months were included in this study.Their clinical data were collected.Logistic regression analysis was performed to establish a predictive model and risk score for aspirin resistance.Hosmer Lemeshow (H-L) test and an area under the receiver operating characteristic (ROC) curve (the area under the ROC curve) were performed to test the calibration and discrimination of the model.Results Seven risk factors were included in the predictive model,including serum creatinine (＞110 μmol/L:score of 1),fasting blood glucose (＞7.0 mmol/L:score of 1),hyperlipidemia (score of 1),number of coronary arteries in lesion (2 branches:score of 2,≥≥3 branches:score of 4),body mass index[(20-25) kg/m2:score of 2,＞25 kg/m2:score of 4],percutaneous coronary intervention (score of 2),smoking (score of 3).H-L test showed P≥0.05 and the area under the ROC curve＞0.70 in this model.Conclusions the risk factors for aspirin resistance,and establishing a valid predictive model for aspirin resistance,could provide an important reference for anti-platelet therapy in CHD patients.

Objective To investigate the synergetic effect of Aiyishu injection in combination with neoadjuvant chemotherapy in the treatment patients with breast cancer.Methods Seventy patients with breast carcinoma at stage Ⅰ - Ⅲ were randomly divided into treatment group( Aiyishu associated CAF regimen)( n =36) and control group ( CAF regimen) ( n =34).The activities of T cells and NK cells,response rate,change of clinical symptoms,adverse effects and living quality were evaluated in patients of two groups.Results The levels of CD3,CD4,CD8 and the ratio of CD4/CD8 and the activity of NK cells in treatment group were higher than those in control group( P ＜0.05) ;the response rate was 41.67％ and 36.67％ in group 1 and 2 respectively,but had no significant difference;the incidence rates of leucopenia and gastrointestinal disturbance were 33.33％ and 38.89％ respectively in patients of treatment group,whereas the rates were 67.65％ and 67.65 ％,in control group ( P ＜ 0.05).In treatment group,KPS increased in 36.11％ (13/36) patients,and it was higher than that in control group (11.76％,4/34 )( P ＜0.05).Conclusion Aiyishu injection can increase the ability of immunity of body and reduce the toxic and adverse reaction,and improve the living quality in patients with breast cancer when it is used in pre-operative chemotherapy of breast cancer.